Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 5/20 | 0.43 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27666282 | 0.79 | GBA1 (0.59) | POLBGBA1PLGSLC6A4 | |
| SCHEMBL167190 | 0.77 | POLB (0.89) | POLBGBA1LTA4H | |
| SCHEMBL167189 | 0.77 | POLB (0.89) | POLBGBA1LTA4H | |
| SCHEMBL1860551 | 0.77 | POLB (0.89) | POLBGBA1LTA4H | |
| SCHEMBL1502350 | 0.76 | CCR3 (0.48) | POLBGBA1SLC6A4 | |
| SCHEMBL25075404 | 0.76 | SLC6A4 (0.45) | POLBGBA1PLGSLC6A4 | |
| SCHEMBL5692520 | 0.75 | POLB (0.63) | POLBGBA1LTA4HPLG | |
| SCHEMBL4373212 | 0.75 | POLB (0.42) | POLB | |
| SCHEMBL1761058 | 0.74 | EED (0.61) | POLBGBA1SLC6A4 | |
| SCHEMBL3473180 | 0.74 | EED (0.61) | POLBGBA1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2256114-B1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-7906510-B2 | Amide derivative and pharmaceutical composition containing the same | Dainippon Sumito Pharma Co., Ltd. (JP) | 2011-03-15 | — | — | US | disclosed |
| EP-2256114-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | HTR4, MC2R, HTR1D | POLB 4784/4885GBA1 3963/4885LTA4H 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.